Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

Gordon, Michael; Margolin, Kim; Talpaz, Moshe; Sledge, George W.; Holmgren, Eric; Benjamin, Robert S.; Stalter, Susan; Shak, S.; Adelman, Daniel C.

doi:10.1200/jco.2001.19.3.843

Cited by 875 publications

(497 citation statements)

References 12 publications

Supporting

Mentioning

461

Contrasting

Unclassified

Order By: Relevance

“…Note however that this did not take account of the context of that practice as either research or clinical. So bevacizumab is dated as 2001 because of its first use in advanced solid tumours at that time (Gordon et al 2001).…”

Section: Supplementary Materialsmentioning

confidence: 99%

The evidence that evidence-based medicine omits

Clarke

Gillies

Illari

et al. 2013

Preventive Medicine

View full text Add to dashboard Cite

According to current hierarchies of evidence for EBM, evidence of correlation (e.g., from RCTs) is always more important than evidence of mechanisms when evaluating and establishing causal claims. We argue that evidence of mechanisms needs to be treated alongside evidence of correlation. This is for three reasons. First, correlation is always a fallible indicator of causation, subject in particular to the problem of confounding; evidence of mechanisms can in some cases be more important than evidence of correlation when assessing a causal claim. Second, evidence of mechanisms is often required in order to obtain evidence of correlation (for example, in order to set up and evaluate RCTs). Third, evidence of mechanisms is often required in order to generalise and apply causal claims.While the EBM movement has been enormously successful in making explicit and critically examining one aspect of our evidential practice, i.e., evidence of correlation, we wish to extend this line of work to make explicit and critically examine a second aspect of our evidential practices: evidence of mechanisms.

show abstract

Section: Supplementary Materialsmentioning

confidence: 99%

The evidence that evidence-based medicine omits

Clarke

Gillies

Illari

et al. 2013

Preventive Medicine

View full text Add to dashboard Cite

show abstract

“…26 the role of veGF in thyroid signaling is uncertain. 40,41 unlike treatment with antiangiogenic tKis, bevacizumab is not associated with altered thyroid homeostasis. 42,43 other factors, such as platelet derived growth factor α and c Kit, have roles in thyroid homeostasis, but so far no data have been published.…”

Section: Reviewsmentioning

confidence: 99%

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

et al. 2009

View full text Add to dashboard Cite

“…[19][20][21][22][23] Phase 1 studies in various solid tumors demonstrated a half-life of nearly 3 weeks, and no dose-limiting toxicities. 24,25 With this safety information, and in light of remarkable successes in other cancers including those of the breast and colon, oncologists began to use bevacizumab for the treatment of patients with recurrent glioblastoma. In the first such report, 21 patients were presented who received bevacizumab and irinotecan as salvage therapy for recurrent glioblastoma.…”

Section: Early Study Of Bevacizumab In Patients With Recurrent Glioblmentioning

confidence: 99%

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Field

Jordan

Wen

et al. 2014

Cancer

View full text Add to dashboard Cite

Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given recent clinical trials that have raised questions regarding its clinical effectiveness, the optimal timing of its use and the validity of endpoints, among other issues. In addition, uncertainty has recently arisen regarding the effects of bevacizumab on quality of life and neurocognitive function, two key clinical endpoints of unquestionable significance among glioblastoma patients. In this review, we highlight these controversies and other recent work related to bevacizumab for glioblastoma. Cancer 2015;121:997

show abstract

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

Cited by 875 publications

References 12 publications

The evidence that evidence-based medicine omits

The evidence that evidence-based medicine omits

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

Contact Info

Product

Resources

About